Tectonic Therapeutic, Inc.
TECXHeld by 5 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying5 funds opened new positions. Next phase2 readout (TX000045- Dose A): Oct 2026. Short interest: 23.9% of float.
Held by 5 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying5 funds opened new positions. Next phase2 readout (TX000045- Dose A): Oct 2026. Short interest: 23.9% of float.
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.